APA (7th ed.) Citation

Emens, L. A., Molinero, L., Loi, S., Rugo, H. S., Schneeweiss, A., Diéras, V., . . . Schmid, P. (2021). Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. JNCI : Journal of the National Cancer Institute, 113(8), 1005-1016. https://doi.org/10.1093/jnci/djab004

Chicago Style (17th ed.) Citation

Emens, Leisha A., et al. "Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study." JNCI : Journal of the National Cancer Institute 113, no. 8 (2021): 1005-1016. https://doi.org/10.1093/jnci/djab004.

MLA (9th ed.) Citation

Emens, Leisha A., et al. "Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study." JNCI : Journal of the National Cancer Institute, vol. 113, no. 8, 2021, pp. 1005-1016, https://doi.org/10.1093/jnci/djab004.